Outspoken Oncology

Sayeh Nikpay, PhD, MPH, Vanderbilt University School of Medicine, explains the origins of 340B, how safety net clinics as well as large hospitals became participants in the program, and the possibility of getting rid of the program altogether.

Neeraj Agarwal, MD, professor of medicine, University of Utah, discusses management decisions for patients with advanced or metastatic prostate cancer, including weariness in using ADT for many patients with comorbidities and how clinicians are currently weighing existing regimens.

Neeraj Agarwal, MD, professor of medicine, University of Utah, discusses management decisions for patients with advanced or metastatic prostate cancer, including weariness in using ADT for many patients with comorbidities and how clinicians are currently weighing existing regimens.

Daniel Goldstein, MD, discusses the ability of interventional pharmacoeconomics to lower drug costs and increase access around the world, as well as the dilemma physicians face for treating patients with a person-centered vs a population health approach.

Daniel Goldstein, MD, discusses the ability of interventional pharmacoeconomics to lower drug costs and increase access around the world, as well as the dilemma physicians face for treating patients with a person-centered vs a population health approach.

John Mandrola, MD, cardiac electrophysiologist at Baptist Health (Louisville, KY), explains how all medical evidence is flawed and a critical mistake HCPs can make with overgeneralizing the results of clinical trials.

John Mandrola, MD, cardiac electrophysiologist at Baptist Health (Louisville, KY), explains how all medical evidence is flawed and a critical mistake HCPs can make with overgeneralizing the results of clinical trials.

Stacie Dusetzina, PhD, department of health policy, Vanderbilt University School of Medicine, discusses the "desensitization" of society to cancer prescription drug costs, the role of advancing science in research and development and drug approvals for rare diseases, the H.R.3 bill in front of Congress, and solutions proposed by politicians for inflated Medicare Part D spending, among other topics.

To read more about our host Chadi Nabhan and access exclusive materials and information about guests, visit journalofclinicalpathways.com/podcasts/outspoken-oncology.

Journal of Clinical Pathways is the exclusive producer of the Outspoken Oncology podcast.

Stacie Dusetzina, PhD, department of health policy, Vanderbilt University School of Medicine, discusses the "desensitization" of society to cancer prescription drug costs, the role of advancing science in research and development and drug approvals for rare diseases, the H.R.3 bill in front of Congress, and solutions proposed by politicians for inflated Medicare Part D spending, among other topics.

To read more about our host Chadi Nabhan and access exclusive materials and information about guests, visit journalofclinicalpathways.com/podcasts/outspoken-oncology.

Journal of Clinical Pathways is the exclusive producer of the Outspoken Oncology podcast.

Michael Thompson, MD, PhD, Advocate Aurora Health Care, discusses social determinants of health, eligibility criteria, and other barriers to clinical trial enrollment in the community setting, as well as the importance of real-world evidence in moving the needle for oncology care.